Reserpine as a Potential Therapeutic Agent for Cardiovascular Disorders: A Comprehensive Review

Read full text Summarise with VIRAT
Authors: Dr. Neeraj Jain1 , Dr. Neelam Jain2 , Pragati Mishra3, Suraj Neupane4, Devendra5, Utkarsh Tiwari6, Amrit Jaiswal7, Abhishek Yadav8, Richa Mishra9, Ankita Tripathi10
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Cardiovascular disorders continue to be a leading cause of morbidity and mortality worldwide, necessitating ongoing research for novel therapeutic interventions. Reserpine, an indole alkaloid derived from the Indian snakeroot plant (Rauvolfia serpentina), has garnered significant interest as a potential candidate for managing cardiovascular conditions. Reserpine's primary mechanism of action involves inhibiting the vesicular uptake of neurotransmitters, leading to a reduction in sympathetic nervous system activity. This results in vasodilation and decreased cardiac output, making it a valuable option for hypertension management. Several clinical studies have demonstrated its efficacy in lowering blood pressure and improving overall cardiovascular health. Furthermore, reserpine exhibits antiarrhythmic properties by stabilizing electrical activity in the heart, which may be beneficial in arrhythmia management. Hence, reserpine presents a promising avenue for the management of cardiovascular disorders, particularly in cases of hypertension and arrhythmias. Its unique mechanism of action makes it an attractive option, albeit with some associated risks. Therefore this comprehensive review examines the potential of reserpine in the context of cardiovascular disorders, encompassing its pharmacological properties, mechanisms of action, and clinical applications.

Fields of Study & Subjects

Blood Pressure and Hypertension Studies Alkaloids: synthesis and pharmacology Cardiac electrophysiology and arrhythmias

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
25 March 2026
Language
EN